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Abstract
Background: Migraine is characterized by headache with symptoms such as intense pain, nausea, vomiting,
photophobia, and phonophobia that significantly impact individuals’ lives. The objective of this study was
to develop a strategy to measure outcomes from the patients’ perspectives for use in evaluating preventive
treatments for migraine.
Methods: This study used a multi-stage process. The first stage included concept identification research through
literature review, patient-reported outcome (PRO) instrument content review, and clinician interviews, and
resulted in a list of concepts relevant to understand the migraine experience. These results informed the design
of the subsequent concept elicitation stage that involved qualitative interviews of adults with migraine to
understand their experiences. Information from these two stages was used to develop a conceptual disease
model (CDM) of the migraine experience. This CDM was used to identify concepts of interest (COI) to evaluate
patient-relevant outcomes for assessing treatment benefit of migraine prophylactics. In the final stage, existing
PRO instruments were reviewed to assess coverage of concepts related to the selected COI.
Results: Nine articles from 563 screened abstracts underwent full review to identify migraine-relevant concepts.
This concept identification and subsequent concept elicitation interviews (N = 32; 21 episodic migraine; 11 chronic
migraine) indicated that people with migraine experience difficulties during and between migraine attacks with
considerable day-to-day variability in the impact on movement, ability to perform every day and social activities,
and emotion. The CDM organized concepts as proximal to and more distal from disease-defining migraine
symptoms, and was used to identify impact on physical function as the key COI. The item level review of PRO
instruments revealed that none of the existing PRO instruments were suitable to collect data on impact of
migraine on physical functioning, to evaluate treatment benefit.
Conclusions: The impact of migraine includes impairments in functioning during and between migraine attacks
that vary considerably on a daily basis. There is a need for novel PRO instruments that reflect patients’ migraine
experience to assess treatment benefit of migraine prophylactics. These instruments must evaluate the concepts
identified and be able to capture the variability of patients’ experience.
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Background
Migraine is a common and often debilitating neurologic
condition characterized by primary recurrent headaches
lasting 4 to 72 h with at least two of the following pain
characteristics: unilateral, pulsating, moderate or severe
intensity, or aggravated by routine physical activity. In
addition, migraine attacks are often accompanied by
nausea, vomiting, and sensitivity to light (photophobia)
and sound (phonophobia) [1]. Based on the International
Headache Society (IHS) guidelines, migraine is classified
as episodic (EM) or chronic (CM), with CM defined
having 15 or more headache days of which at least 8
meet the criteria for a migraine for at least three months
(IHS Classification ICHD-III) [1].
Migraine is about three times more common in women
than men, affecting roughly 18 % of women and 6 % of
men in the United States [2–8]. Migraine prevalence
estimates are fairly comparable across the world, with
11.5 % of adults meeting criteria for a migraine on aver-
age [9]. Prevalence is highest during an individual’s
peak productivity years, between the ages of 25 and 55
[2, 4], where it has significant impact on daily life with
substantial functional impairment that include both
physical and emotional ramifications [10]. More than
half of people with migraine require bed rest to manage
their pain [11], leading to work/school absenteeism
[12]. Estimates of the burden of migraine suggest that
the average impact of migraine on worker productivity
is approximately a loss of four workdays per year and
10 days of reduced productivity [13, 14]. In addition to
lost wages and productivity due to absenteeism, many
people with migraine also experience reduced product-
ivity while at work [13].
In addition to the substantial impairment during attacks
(ictal burden), migraine also causes impairment between
attacks (interictal burden). When compared with indi-
viduals without migraine, migraineurs report reduced
health-related quality of life even during pain-free pe-
riods [15, 16]. Interictal burden can include anxiety,
anticipation of the next attack, and avoidance of activ-
ities due to fear of migraine or headache. This can lead
to impairment in work or school, impairment in family
and social life, difficulty making plans or commitments,
and emotional/affective and cognitive distress [17].
Migraine headaches are commonly treated acutely.
Acute treatments range from the use of non-specific
acute migraine medications including simple analgesics
such as nonsteroidal anti-inflammatory drugs (NSAIDs) or
acetaminophen for mild to moderate attacks to migraine-
specific acute treatments including triptans and ergot-
derivatives for moderate to severe attacks [18–20]. Opioids
are reserved for patients with moderate to severe pain who
do not respond to, or cannot tolerate non-opioid medica-
tions [18–20]. Based on published treatment guidelines,
roughly 40 % of the migraine population would also benefit
from preventive therapy [21]. However, only approximately
12 % of people with migraine receive any preventive ther-
apy due in part to limited efficacy and significant tolerability
and safety issues with available preventive therapies, indi-
cating a large unmet medical need for migraine prophy-
laxis [21]. The aim of prophylactic treatments for migraine,
such as antiepileptics, antidepressants, and antihyperten-
sives, is not only to reduce migraine frequency, but also
reduce disability and restore the ability to function [22, 23].
To evaluate the benefit of preventive treatments, it is
important to examine whether the treatment is associ-
ated with a reduction in the impact of migraine on a
patient’s life. Thus, guidelines for clinical trials of mi-
graine treatments recommend the inclusion of Patient
Reported Outcome (PRO) instruments to support clinical
trial endpoints [24]. PRO instruments included in trials
should be sensitive to changes resulting from treatment in
the context of clinical trials and reflect the experiences of
people with the condition, in this case migraine. In order
for PRO instruments to be used to evaluate treatment
benefit to support label claims, evidence of the relevance
of symptoms and impacts on function or quality of life
concepts to the target sample is required by the United
States Food and Drug Association (FDA) [25]. The
European Medicines Agency have defined health-related
quality of life (HRQL) as a broad outcome concept that
includes, “the patient’s subjective perception of the impact
of his disease and its treatment(s) on his daily life, phys-
ical, psychological and social functioning and well-being”
in the context of evaluating treatment benefit [26].
Although numerous PRO instruments have been used in
migraine studies [27], their suitability to evaluate the treat-
ment benefits of preventive migraine treatments has not
been explored. Thus this study sought to identify impacts
of migraine that are most relevant to those with EM and
CM. The objective of this study was to develop a strategy
to measure outcomes from the patients’ perspective for
use in evaluating preventive treatments for migraine.
Methods
This study used a multi-stage process. An overview of
the flow of the project is illustrated in Fig. 1. The first
stage (concept identification through literature review,
PRO instrument content review, and clinician interviews)
resulted in a list of concepts relevant to understand the ex-
perience of people with migraine. These results informed
the design of the subsequent concept elicitation stage that
involved qualitative interviews with subjects with migraine
to understand their experiences. The information from
these two stages was used to develop a conceptual dis-
ease model (CDM) of the experience of migraine. This
CDM was used to identify concepts of interest (COI) to
evaluate patient relevant outcomes. Finally, existing PRO
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instruments were reviewed for coverage of concepts re-
lated to the selected the COI to ensure reflection of the
patients’ experience of migraine.
The methods and results from each stage of the research
are presented in chronological order: concept identifica-
tion (Stage 1), concept elicitation (Stage 2), development
of a CDM (Stage 3), selection of COI (Stage 4), and item
level review of the content of PRO instruments to identify
best instrument to measure the COI (Stage 5).
Results and Discussion
Concept identification (stage 1)
Concept identification research was conducted to under-
stand the impact of migraine in adults. This stage included
identifying a list of concepts describing the experience of
the impact of migraine symptoms in order to develop a
CDM and identify the COI.
Concept identification methods
A focused literature review was conducted to identify con-
cepts that reflect patient experiences of migraine. Articles
published between 1998 and 2013 reporting qualitative
studies related to migraine were identified using key search
terms of EMBASE/MEDLINE databases.. Articles selected
were reviewed to identify concepts relevant to understand
patients’ experience of the impact of migraine. The articles
included qualitative studies about individuals’ experience of
migraine/headache and its impacts, methodology papers
about gathering information on headache/migraine-related
impairment, and migraine impact studies.
Next, migraine PRO instruments were identified through
a focused search of published articles, including publi-
cations on clinical trials and validation studies, through
key literature databases (EMBASE/MEDLINE, PsycInfo,
and International Pharmaceutical Abstracts) between
2010 and 2012. The PRO instruments identified were
reviewed to identify concepts relevant to evaluating the
experiences of migraine patients in clinical trials. A pre-
liminary concept list was developed based on the steps
above. This list was reviewed by three clinicians in order
to provide expert feedback.
Concept identification results
In the literature review a total of 563 abstracts were
screened. Abstracts related to epidemiological studies,
randomized clinical trials, health economic studies, quan-
titative studies, and development and validation studies
were excluded. Nine articles relevant to the objectives of
the review were retrieved for full text review [14, 28–35].
The specific impact concepts identified were related to
1) performing day-to-day activities (e.g., at work or school;
household chores/tasks); needing to rest, lie down, or
sleep), 2) participating in social and leisure activities (e.g.,
engaging in social activities; being able to participate in leis-
ure activities; maintaining relationships; engaging in sexual
activity), 3) emotional responses (e.g., feeling irritable or
frustrated; experiencing depressed mood; anxiety, concern
or worry in response to migraine), and 4) cognitive difficul-
ties (e.g., ability to concentrate; ability to think clearly).
Twenty-one PRO instruments were reviewed for the
concept identification review. These PRO instruments in-
cluded items to collect data about migraine symptoms as
well as impacts of migraine. Common impact concepts in-
cluded, impact on work-productivity (e.g., mean number
of hours/days of work lost and of restricted activity; cost
of restricted activity; total rate of lost productivity, in
hours, per migraine subject), impact on emotions (e.g.,
worrying about migraine, anxiety in anticipation of the
next migraine, phobic avoidance of activities for fear of
migraine headache) and social function (e.g., sexual life,
Fig. 1 Flow Diagram of the Multi-Stage Project
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love, friends, social position, leisure time, family situation),
and psychological stress (e.g., depression, emotional dis-
tress and affective distress).
A preliminary concept list developed based on the steps
above was reviewed by three migraine experts. All three
migraine experts routinely managed migraine patients in
clinic settings, as well as conducted research in migraine.
Migraine experts’ feedback was elicited via interviews to
ensure clinical relevance, and the concept list was revised
to exclude items that were not clinically relevant to under-
standing patients’ experience of the impact of migraine
(e.g., co-morbid conditions were excluded).
Concept elicitation (stage 2)
The FDA guidance document for industry, “Patient-
Reported Outcome Measures: Use in Medical Product
Development to Support Labeling Claims” emphasizes the
importance of conducting qualitative research throughout
the process of instrument development to ensure that the
content of the measure is consistent with patients’ experi-
ences and to ensure that the concepts measured by the
instrument cover what patients consider most import-
ant about their condition [25, 36]. Stage 2 of the re-
search involved the design and conduct of a qualitative
concept elicitation study.
Concept elicitation methods
A qualitative research protocol, including an interview
guide specifically designed to elicit concepts from patients
with migraine, was developed based on the results from
Stage 1. Concept elicitation interviews were conducted
with 32 adult subjects with migraine to explore patients’
experience of the impact of migraine. Adult subjects (18
to 60 years of age) with EM or CM (IHS Classification
ICHD-II) with or without aura were recruited through five
clinical sites across the United States between August and
October 2013. Subjects were recruited using a standard
screening script to introduce the study consistently to all
subjects. Subjects had to have a history of migraine head-
ache for at least 12 months with at least four headache-
free days per month and have experienced a migraine
headache within two weeks prior to screening. Key exclu-
sion criteria included migraine onset older than 50 years
of age, more than one migraine lasting more than 72 h
within three months prior to screening, and cognitive
impairment preventing participation in the interview.
Subjects with generalized anxiety disorder or major de-
pression were permitted in the study if they were on
monotherapy treatment, had not experienced a medica-
tion adjustment in the 3 months prior to screening and
demonstrated clinical stability. All subjects provided
written informed consent prior to data collection proce-
dures. All study procedures were approved by an Institu-
tional Review Board (IRB).
One-on-one in-person interviews were conducted by
researchers trained and experienced in qualitative inter-
viewing methods. A semi-structured interview guide was
used for the discussions during the concept elicitation
interviews (Table 1). The interview guide was designed
to elicit concepts about the subjects’ current experiences
with migraine, such as the impact of symptoms on func-
tioning. Interviews started with open ended questions
for concept elicitation followed by probes on the con-
cepts identified from Stage 1. Each interview was audio-
recorded and subsequently professionally transcribed for
analysis.
Qualitative analyses
A saturation grid based on interviewer notes was devised
to establish and document saturation as suggested by
ISPOR Task force [37]. Saturation is defined as the point
at which no substantially new themes, descriptions of a
concept, or terms are introduced as additional interviews
are conducted [38]. Each subject interview was grouped
Table 1 Outline of the concept elicitation guide
Themes to be explored Examples of questions
1. History of migraine Diagnosis, medications, treatments
2. Migraine symptoms How often? How much intensity/severity)? When?
3. Exploration of symptom impact/impact on functioning migraine has
on subject’s life
How is your life impacted by your migraines?
4. Impact migraine symptoms have on subject’s physical function How is your physical function affected by your migraines?
5. Impact migraine symptoms have on subject’s ability to do day-to-day
activities
How is your everyday activity affected by your migraines?
6. Impact migraine symptoms have on subject’s social or recreational
activities
How are your social or recreational activities affected by your
migraines?
7. Impact migraine symptoms have on subject’s relationships How is your personal or family life affected by your migraines?
8. Impact migraine symptoms have on subject’s emotions How are your emotions affected by your migraines?
9. Exploring cognitive impact migraine symptoms have on subject’s life What cognitive impact from migraines have you noticed in your life?
10. Overall ranking What aspect of having a migraine has the MOST IMPACT on your life?
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by sets of five successive subjects to aid with evaluating
saturation (i.e., the first five subjects were grouped to-
gether, the next five subjects were grouped together,
etc.). To ensure that saturation was achieved, structured
counts were taken during each interview for the number
of interview subjects that endorsed emergent concepts
along with review of the coded ATLAS.ti outputs.
Transcript data was imported into ATLAS.ti (version
7.1) qualitative data analysis software (Scientific Software
Development GmbH) and analyzed using an open coding
approach. Patient statements (e.g., words and phrases)
were systematically categorized to identify concepts both
distinct to each subject’s experience and common to the
experience of migraine. A coding dictionary was then de-
veloped based on the concepts that emerged and was
expanded as necessary to include emergent concepts that
arose during the interviews. The coding dictionary was
used to label the patient statements with codes to capture
the concepts and themes for analyses.
Concept elicitation results
Of the 32 migraineurs (21 EM; 11 CM) interviewed, most
(n = 27; 84 %) were female and their mean (SD) age was
40.3 (11.3) years (Table 2). Subjects reported experiencing
7.5 (4.1) [mean (SD)] migraine attacks each month. Sub-
jects discussed how the impacts of migraine varied day to
day. For example the intensity of the migraine often had a
direct and immediate impact on their ability to function
during and after the episode. Impacts on physical func-
tioning from migraine symptoms were reported by more
than 50 % of subjects. A total of 28 (88 %) subjects spon-
taneously reported that migraine impacted their physical
ability. Impact on physical ability mentioned included -
needing to rest or lie down (n = 32; 100 %), difficulty with
moving one’s head (n = 28; 88 %) or body (n = 26; 81 %),
bending over (n = 26; 81 %), walking (n = 26; 81 %), getting
out of bed (n = 26; 81 %), and doing activities requiring
physical effort (n = 26; 81 %) — especially during the
migraine. A total of 25 (78 %) of subjects spontaneously
reported that migraine in some way affected their abil-
ity to do everyday activities. Impact on everyday activ-
ities included missing school or work (n = 30; 94 %),
difficulty doing daily chores or errands outside the
home (n = 29; 91 %), difficulty caring for others (n = 27;
84 %), being unable to do activities in the presence of
loud noises (n = 25; 78 %) or bright lights (n = 24; 75 %),
reduced performance in work/school activities (n = 25;
78 %), being unable to do activities requiring concentra-
tion (n = 25; 78 %) or clear thinking (n = 23; 72 %), diffi-
culty with self-care tasks (n = 20; 63 %), and an inability to
keep a schedule (n = 14; 44 %).
A total of 22 (69 %) subjects spontaneously reported
that migraine affected their social and leisure functioning,
including their participation in social events, hobbies,
exercise, and activities with family. When probed about
the impacts of migraine on social and leisure function-
ing, 91 % (n = 29) endorsed at least one type of impact.
Impact on social/leisure functioning included impacts
on spending time with family (n = 29; 91 %), limiting
social interactions (n = 25; 78 %), impact on hobbies
(n = 24; 75 %), impact on partner/spouse relationships









Age (years), mean (SD) 40.3 (11.3) 39.7 (11.1) 41.5 (12.1)
Sex (female), n (%) 27 (84.4) 17 (81.0) 10 (90.1)
Ethnicity (not Hispanic or Latino),
n (%)
28 (87.5) 17 (81.0) 11 (100)
Race, n (%)a
White 26 (81.3) 17 (81.0) 9 (81.8)
Black or African American 6 (18.8) 3 (14.3) 3 (27.3)
American Indian or Alaska Native 2 (6.3) 1 (4.8) 1 (9.1)
Other 1 (3.1) 0 (0) 1 (9.1)
Employment status, n (%)a
Employed, full-time 19 (59.4) 15 (71.4) 4 (36.4)
Employed, part-time 10 (31.3) 5 (23.8) 5 (45.5)
Student 2 (6.3) 2 (9.5) 0 (0)
Unemployed 1 (3.1) 0 (0) 1 (9.1)
Other 1 (3.1) 0 (0) 1 (9.1)
Highest level of education, n (%)
Secondary/high school 3 (9.4) 0 (0.0) 3 (27.3)
Some college 14 (43.8) 10 (47.6) 4 (36.4)
College degree 13 (40.6) 10 (47.6) 3 (27.3)
Postgraduate degree 2 (6.3) 1 (4.8) 1 (9.1)
Migraine diagnosis duration (years),
mean (SD)
14.3 (9.7) 12.2 (8.4) 18.5 (11.0)
Migraine interference with daily activities in past week, n (%)
Not at all (0) 1 (3.1) 1 (4.8) 0 (0)
Mildly (1–3) 5 (15.6) 2 (9.5) 3 (27.3)
Moderately (4–6) 14 (43.8) 10 (47.6) 4 (36.4)
Markedly (7–9) 9 (28.1) 6 (28.6) 3 (27.3)
Extremely (10) 3 (9.4) 2 (9.5) 1 (9.1)
Did you miss work or school due to migraine related symptoms in the
past week? n (%)
Yes 9 (28.1) 7 (33.3) 2 (18.2)
No 20 (62.5) 14 (66.7) 6 (54.6)
I do not attend work or school 3 (9.4) 0 (0) 3 (27.3)
Treatments taken to treat migraines when they occur, n (%)a
Over the counter/non-prescription
medication
24 (75) 19 (90.5) 5 (45.6)
Prescription drug 18 (56.3) 10 (47.6) 8 (72.7)
aNot mutually exclusive
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(n = 20; 63 %), impact on traveling and vacationing (n = 20;
63 %), and impact on social activities around loud noises
(n = 14; 44 %) or bright lights (n = 13; 41 %).
Over half of the subjects spontaneously reported the
emotional impact of their migraine (n = 19; 59 %). When
probed about the emotional impacts of migraine, 97 %
(n = 31) endorsed at least one type of emotional impact.
Emotional impact included feeling frustrated or irritated
(n = 31; 97 %), feeling like a disruption to others when
migraine attacks occur (n = 29; 91 %), feeling like a burden
to others (n = 27; 84 %), feeling disappointed or discour-
aged (n = 26; 81 %), worrying (n = 27, 84 %), feeling a lack
of control (n = 20; 63 %), an impact on the ability to show
affection (n = 16; 50 %), and feeling embarrassed over
impairments (n = 13; 41 %).
Subjects with EM and CM experienced wide variability
in the frequency, duration, and severity of their migraines;
however, the same impacts of migraines on physical, so-
cial, emotional function, and were described by both CM
and EM subjects.
Saturation was reached for EM participants after 15
interviews and for CM participants after 10 interviews.
An example of evidence of saturation for physical func-
tioning is shown in Fig. 2. Table 3 presents a selection of
subject quotes for the key themes related to the impact
of migraine.
Development conceptual disease model (stage 3)
A conceptual disease model is a pictorial representation
of disease processes. A CDM might include information
about pathophysiology, natural history, known signs and
symptoms, and hypothesized or known outcomes of
disease. Development of a CDM is considered a good
research practice to help determine which concepts might
be helpful to measure using a PRO instrument, in a spe-
cific context of use [37].
A CDM was developed based on the results of Stages 1
and 2. The list of concepts identified in Stage 1 and the
concepts that endorsed by subjects in Stage 2, were uti-
lized to draft a CDM that visually organized the key con-
cepts which reflect the patients’ experiences of migraine.
The CDM was developed to identify and prioritize con-
cepts of interest and to aid in selecting endpoints to evalu-
ate treatment benefits of migraine prophylactics from the
patients’ perspective.
The model was further refined based on outputs of struc-
tured interviews conducted with two neurologists with ex-
pertise in treating migraine patients, a clinical psychologist
with expertise in headache and pain management, and an
instrument development expert with expertise in migraine-
specific PRO tools. Input from the experts was used to
revise the model to ensure that the impacts of migraine
discussed by the patients were specific to migraine, a
result of migraine symptoms (and not comorbid condi-
tions), and were relevant for both EM and CM. Clini-
cians also indicated it would be helpful for the model
to differentiate concepts that were considered disease
defining symptoms of migraine (e.g., photophobia) from
concepts that could be a result of co-morbid conditions
in the target sample (e.g., sleep difficulties, depression).
The resulting CDM (Fig. 3) illustrates the key concepts
that reflect the patients’ experiences of the disease, and
shows how some impacts are more temporally proximal
to migraine symptoms.
Fig. 2 Evidence of Saturation for Physical Functioning
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Selection of concept of interest (stage 4)
The PRO strategy team used the CDM as a visual aid
to help identify the COIs for evaluation of outcomes of
prophylactic treatments for migraine. Criteria used to
inform the selection of the concept of interest included:
at least 50 % of CM and EM subjects needed to experi-
ence the impact, consideration of specificity to migraine
versus impacts due to additional clinical issues in mi-
graine patients (e.g. comorbid conditions such as de-
pression or anxiety, tolerability issues associated with
acute and prophylactic migraine treatments), and aspects
related to the context of use of the PRO (e.g., study design
aspects like the duration of observation and the potential
for the concept to change within that time frame).
The team proposed that the direct impacts of prevent-
ing migraines would be experienced in terms of changes
in impact on physical functioning. These in turn would
also result in changes in the impacts on social functioning
and emotional responses to migraine. Impact on physical
functioning was therefore selected as the COI that would
be most important to evaluate the immediate benefits
of interventions that prevented migraines. Evidence of
changes in this COI would most likely be observed over
a shorter duration of time (approximately 6 months).
Concepts temporally distal to migraine symptoms, like
the impacts on social and leisure activities and emotional
aspects may take a little longer to improve and would be
important concepts to assess in the longer term.
Item level review of content of PRO instruments to
evaluate measurement of the COI (stage 5)
An item level review of existing PRO instruments was
conducted to determine whether published PRO instru-
ments would be suitable to evaluate the COI selected in
Stage 4 - changes in the impact of migraine on physical
functioning. Items from each of the existing migraine
PRO instruments identified in Stage 1 were reviewed to
determine whether they included items that could evalu-
ate the concepts related to physical functioning as re-
ported by the patients in the Stage 2 concept elicitation
interviews.
Based on this review, five instruments were identified
as potentially relevant for measuring the COI and were
the most common migraine PRO instruments identified
in clinical studies of migraine therapy: The Migraine Dis-
ability Assessment questionnaire (MIDAS) [39]; Migraine-
Assessment of Current Therapy (Migraine-ACT) [40];
Headache Impact Test (HIT-6™) [41]; Migraine Specific
Quality of life questionnaire (MSQ) [42]; and the Patient
Perception of Migraine Questionnaire (PPMQ-R) [43].
However, the PPMQ-R only measured satisfaction with
acute migraine treatments and Migraine-ACT was devel-
oped only to identify patients requiring a change in their
current acute therapy. These two instruments were there-
fore not considered suitable to evaluate the COI.
The three remaining migraine-specific PRO instruments,
Migraine Disability Assessment questionnaire (MIDAS),
Migraine Specific QoL questionnaire (MSQ) and the
Headache Impact Test (HIT-6), were reviewed in detail
and items were mapped to the physical function concepts
identified during the concept elicitation interviews (Table 4).
In addition, the methods for development and validation of
the three identified instruments were reviewed in depth
to determine compliance with FDA guidelines for de-
velopment of PRO instruments to support label claims
[11]. While these three instruments included a few items
to measure the concepts identified by the subjects in Stage
2 interviews, there was limited evidence to show that they
were suitable to comprehensively evaluate the impact of
migraine on a physical functioning. For example, none of
these instruments included items evaluating difficulty with
moving the head [mentioned by 28 patients (88 %) during
the CE interviews], difficulty with moving one’s body,
getting out of bed, walking, or doing activities requiring
Table 3 Example quotes by domain
Domain Episodic migraine quote Chronic migraine quote
Physical functioning You just don’t move around as much…and you don’t move real
fast, you don’t want to dance, you don’t want to do anything like
that that will kind of jolt your body. (EM no aura)
I don’t like to do anything when I’m in the middle of a
migraine. I mean, even just any slight movement hurts.




Okay. So I’ve had to skip weddings, I’ve had to skip school events,
I’ve had to skip my, uh, grandchild’s, um, baptism I had to skip
because I had a migraine. Um, just activities, you know, just
normal everyday life things that you look forward to. You know,
I haven’t been to gone—do because, you know, migraine and,
um, you know, and I push myself to try to go to this stuff and,
you know, and there’s—then I start throwing up and it’s like, no,
I can’t, you know, so. (EM no aura)
Well, whether it be visiting, uh, parents to, uh, to recreational
sports; whether it be fishing, boating, uh, going to the
beach, or the playground…swimming at a neighbor’s
house, or going out to eat, any, you know, anything like
that. I just wouldn’t do it. (001–006 – CM no aura)
Emotional functioning [Migraines]…just add a lot of stress because of, um, having to
worry about like working around it or working through it or
making arrangements to be able to not have to do things.
(EM aura)
I feel like I’m a burden to people when I have migraines,
you know, because I have to rely on them and my whole
independence is taken away, you know, but, um, when
I don’t have a migraine I’m, you know, I’m happy go lucky.
(CM no aura)
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physical effort [each mentioned by 26 patients (81 %) dur-
ing the CE interviews], or difficulty with self-care tasks
[mentioned by 20 patients (63 %) during the CE inter-
views]. Further, none of the instruments had evidence
of content validity as proposed in the FDA PRO guid-
ance [25].
The MSQ was designed to measure three dimensions: (i)
Role Function-Restrictive; (ii) Role Function-Preventive;
and (iii) Emotional Function in the past four weeks or
in the past week. It was not developed based on con-
cept elicitation interviews with patients with migraine
[42]; therefore, the conceptual fit of the items within each
domain subscale has not been explicitly substantiated.
The HIT-6 was designed to measure impact of headaches;
it is not migraine-specific and also did not involve patient
input during its development [41] it aims to collect data
on the impact of headaches have on the ability to function
on the job, at school, at home and in social situations in
the past 4 weeks. The MIDAS had similar limitations [39]
as it was designed to measure the impact of migraine
headaches to determine the level of pain and disability
caused by migraine in the past 3 months. None of these
three instruments were designed to capture the impact of
migraine on physical functioning and the day-to-day vari-
ability of the experience as reported by patients in the
concept elicitation research.
Fig. 3 Migraine Disease Model – Subjective Experience of Migraine - EM and CM
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Although the existing instruments are useful in estab-
lishing the impact of migraine and its treatment on pa-
tients’ quality of life, the lack of complete coverage of
the immediate impacts of migraine, the inability to cap-
ture the day-to-day variability of ictal and inter-ictal ex-
periences of migraine patients and the lack of evidence
of content validity to meet the FDA guidelines of devel-
opment of PRO tools demonstrates the need for a new
instrument to measure the benefit of prophylactic treat-
ment of migraines.
Conclusion
This study provides a comprehensive assessment of the
functional impact of migraine, specifically those of rele-
vance from the individuals’ perspective. Migraine im-
pacts physical functioning, social and leisure activities,
and also has emotional impacts. These impacts are expe-
rienced during and between migraine attacks and vary
considerably day-to-day. This study utilized an iterative
and multi-faceted approach to understand patients’ expe-
riences of the impact of migraine. The result of concept
identification research and concept elicitation interviews
with migraine patients have been used to develop a CDM
that can be used as a visual guide to select the COI for
developing strategies for measuring outcomes of inter-
ventions for migraine, depending on the context of
evaluation.
The suitability of existing PRO instruments for measur-
ing outcomes, specifically, the impact on physical func-
tioning, in studies of migraine was evaluated. The review
of the existing migraine-relevant PRO tools demonstrated
that many of the existing migraine-related PRO tools
included a few items measuring the impact of migraine
on physical functioning. However, none of these tools
comprehensively covered patients’ experiences (reported
in the concept elicitation interviews) about the impact of














5 3 months On how many days did you miss work or
school because of your headaches?
How many days was your productivity at
work or school reduced by half or more
because of your headaches?
On how many days did you not do
household work because of your headaches?
How many days was your productivity in
household work reduced by half or more
because of your headaches?
Headache Impact Test
(HIT-6)
6 4 weeks How often does your headache limit your
ability to do usual daily activities (household,
work, school, social)?
When you have a headache
how often do you wish you
could lie down?
How often have you felt too tired to do work
or daily activities because of your headache?
How often have you felt too
tired to do work or daily
activities because of your
headache?
How often did your headaches limit your





14 4 weeks How often does your headache limit your
ability to do usual daily activities (household,
work, school, social)?
How often have migraines
left you too tired to do work
or daily activities?
How often have you felt too tired to do work
or daily activities because of your headache?
How often have migraines
limited the number of days
you have felt energetic?
How often did your headaches limit your
ability to concentrate on work or daily
activities?
How often does your headache limit your
ability to do usual daily activities (household,
work, school, social)?
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migraine on physical functioning. There was also limited
evidence to support the content validity of the instru-
ments for use in evaluating treatment benefit for migraine
prophylaxis as per the FDA PRO Guidance [25]. To
evaluate outcomes for preventive treatments fora chronic
condition with episodic flares, such as migraine, PRO in-
struments used ideally should be able to measure the
variability in the impact of migraine on patients’ ability
to function.
The evidence generated thus far strongly supports the
need for new PRO instruments to collect data about the
impact of migraine on physical functioning for use in
evaluating the benefits of preventive treatments for mi-
graine. Such instruments would be useful in evaluating
and monitoring outcomes in both clinical trial and clinical
practice settings. Suggested next research steps include
development of a new PRO instrument for assessing the
impact of migraine on functioning incorporating the con-
cepts identified in this study, reflecting the experiences of
patients with episodic and chronic migraine.
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